Natural product-based Regenerative therapy for T2D: Withaferin A (WFA) promotes reprogramming of adult pancreatic ductal cells into α, δ, and β cells via up regulation of Ngn3, 16/August/2014, 10.21 am

A recent study from the Mammalian Genetics Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom; and School of Medicine, King’s College London, London, United Kingdom shows that “Loss of Fbw7 Reprograms Adult Pancreatic Ductal Cells into α, δ, and β Cells.” This study was published in the August 7  2014 Cell Stem Cell by Prof Axel Behrens, Rocio Sancho, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based Regenerative therapy for T2D:  Withaferin A (WFA), a medicinal compound derived from herb Withania somnifera, promotes  reprogramming of adult pancreatic ductal cells into α, δ, and β cells via up regulation of Ngn3. This study suggests that Withaferin A, by increasing the expression of Ngn3 in adult pancreatic ductal cells, it may reprogram adult pancreatic ductal cells into β cells.  Thereby, it may induce the expression of Ngn3, increase insulin secretion and inhibit insulin resistance. Together, this study suggests that pharmacological formulations encompassing“Withaferin A or its analogues” may be used to regenerate  β cells in T2D patients. 

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation